In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide (Exendin-based GLP-1 receptor agonist) at a dose of 4 or 6 mg than among those who received placebo.